These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22264497)

  • 1. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
    Rubinstein I; Weinberg GL
    Maturitas; 2012 Sep; 73(1):68-73. PubMed ID: 22264497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicines for chronic non-infectious arthritis: the clinician's perspective.
    Rubinstein I; Weinberg GL
    Nanomedicine; 2012 Sep; 8 Suppl 1():S77-82. PubMed ID: 22640912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
    Laurberg TB; Frystyk J; Ellingsen T; Hansen IT; Jørgensen A; Tarp U; Hetland ML; Hørslev-Petersen K; Hornung N; Poulsen JH; Flyvbjerg A; Stengaard-Pedersen K
    J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for reducing inflammation and promoting bone repair in arthritis.
    Neto MF; Yokota H; Figueiredo ML
    Front Biosci (Landmark Ed); 2018 Jan; 23(2):318-347. PubMed ID: 28930550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy.
    Han Y; Huang S
    J Control Release; 2023 Apr; 356():142-161. PubMed ID: 36863691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing micro- and nano-particles for treating rheumatoid arthritis.
    Mitragotri S; Yoo JW
    Arch Pharm Res; 2011 Nov; 34(11):1887-97. PubMed ID: 22139688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy.
    Fang G; Zhang Q; Pang Y; Thu HE; Hussain Z
    J Control Release; 2019 Jun; 303():181-208. PubMed ID: 31015032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of willow bark extract in the treatment of osteoarthritis and rheumatoid arthritis: results of 2 randomized double-blind controlled trials.
    Biegert C; Wagner I; Lüdtke R; Kötter I; Lohmüller C; Günaydin I; Taxis K; Heide L
    J Rheumatol; 2004 Nov; 31(11):2121-30. PubMed ID: 15517622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicines for inflammatory diseases.
    Khaja FA; Koo OM; Önyüksel H
    Methods Enzymol; 2012; 508():355-75. PubMed ID: 22449935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal drug formulations in the treatment of rheumatoid arthritis.
    van den Hoven JM; Van Tomme SR; Metselaar JM; Nuijen B; Beijnen JH; Storm G
    Mol Pharm; 2011 Aug; 8(4):1002-15. PubMed ID: 21634436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-Based Nanomedicine Therapeutics for Rheumatoid Arthritis.
    Rahman M; Beg S; Anwar F; Kumar V; Ubale R; Addo RT; Ali R; Akhter S
    Crit Rev Ther Drug Carrier Syst; 2017; 34(4):283-316. PubMed ID: 29199587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraarticular drug delivery in osteoarthritis.
    Gerwin N; Hops C; Lucke A
    Adv Drug Deliv Rev; 2006 May; 58(2):226-42. PubMed ID: 16574267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug events in rheumatoid arthritis and osteoarthritis ambulatory patients.
    Tragulpiankit P; Chulavatnatol S; Rerkpattanapipat T; Janwityanujit S; Somjarit S; Sirikhedgon U
    Int J Rheum Dis; 2012 Jun; 15(3):315-21. PubMed ID: 22709494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nano - Based Therapeutic Strategies in Management of Rheumatoid Arthritis.
    Nautiyal G; Sharma SK; Kaushik D; Pandey P
    Recent Pat Nanotechnol; 2024; 18(4):433-456. PubMed ID: 37904559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine for the Treatment of Rheumatoid Arthritis.
    Jeong M; Park JH
    Mol Pharm; 2021 Feb; 18(2):539-549. PubMed ID: 32502346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cytokines in osteoarthritis pathophysiology.
    Fernandes JC; Martel-Pelletier J; Pelletier JP
    Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
    Wildy KS; Wasko MC
    Hand Clin; 2001 May; 17(2):321-38, xi. PubMed ID: 11478054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-based Vesicular Nanocargoes as Nanotherapeutic Targets for the Effective Management of Rheumatoid Arthritis.
    Rahman M; Beg S; Sharma G; Saini S; Rub RA; Aneja P; Anwar F; Alam MA; Kumar V
    Recent Pat Antiinfect Drug Discov; 2016; 11(1):3-15. PubMed ID: 27193030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status.
    Gorantla S; Singhvi G; Rapalli VK; Waghule T; Dubey SK; Saha RN
    Ther Deliv; 2020 Apr; 11(4):269-284. PubMed ID: 32434463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.